Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEK162 + Ganitumab in Advanced Solid Tumors
NCT01562899Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Aug 2012
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of binimetinib in colorectal adenocarcinoma, pancreatic adenocarcinoma (PDAC), melanoma, sponsored by Pfizer. Started Aug 2012; status: terminated.
02
Drugs
binimetinib
03
Conditions
colorectal adenocarcinomapancreatic adenocarcinoma (PDAC)melanoma
Beyond the preview
Go deeper on NCT01562899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01562899.